• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does EU Approval Of Oral Wegovy Pill Reshape The Bull Case For Novo Nordisk (CPSE:NOVO B)?

    Simply Wall St·07/16/2026 11:32:08
    Listen to the news
    • Earlier this week, the European Commission granted marketing authorisation for Novo Nordisk’s once‑daily oral Wegovy semaglutide 25 mg pill and a new 7.2 mg Wegovy injection pen for adult obesity and overweight across all EU member states, as an adjunct to diet and physical activity.
    • This makes Wegovy the first GLP‑1 receptor agonist available in tablet form for obesity in Europe, potentially reshaping patient preferences and competitive dynamics in the region’s weight‑management market.
    • We’ll now examine how EU-wide approval of the oral Wegovy pill could influence Novo Nordisk’s investment narrative around GLP‑1 expansion.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Novo Nordisk Investment Narrative Recap

    Novo Nordisk’s investment case still hinges on sustained GLP‑1 adoption in obesity and diabetes, supported by proven clinical data and expanding access. The EU approval of oral Wegovy reinforces that story by broadening treatment formats, but it does not remove near term pressure points such as potential price erosion in core markets or the risk that GLP‑1 volume growth in the US slows more than expected.

    Among recent developments, the collaboration with Vivani Medical to evaluate a semaglutide implant is especially relevant. It highlights Novo Nordisk’s push beyond injections and daily pills into longer acting delivery, which could matter for future GLP‑1 adherence and differentiation. At the same time, this type of innovation keeps capital intensity high, so it interacts directly with the existing risk around elevated manufacturing and R&D spend.

    Yet beneath the strong GLP‑1 story, investors should also be aware that rising generic pressure and high capital spending could still...

    Read the full narrative on Novo Nordisk (it's free!)

    Novo Nordisk's narrative projects DKK325.6 billion revenue and DKK102.6 billion earnings by 2029. This implies fairly flat yearly revenue growth and an earnings decrease of about DKK19.4 billion from DKK122.0 billion today.

    Uncover how Novo Nordisk's forecasts yield a DKK316.91 fair value, a 4% downside to its current price.

    Exploring Other Perspectives

    CPSE:NOVO B 1-Year Stock Price Chart
    CPSE:NOVO B 1-Year Stock Price Chart

    Some of the lowest ranked analysts were expecting Novo Nordisk’s revenue to fall to about DKK 274.0 billion and earnings to around DKK 79.6 billion by 2029, so if you see oral Wegovy’s EU approval as a positive shift, it may challenge that more pessimistic view and is a reminder that reasonable people can look at the same company and reach very different conclusions.

    Explore 65 other fair value estimates on Novo Nordisk - why the stock might be worth over 2x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
    • Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.